TABLE OF CONTENTS
Volume 79, Issue 3 (March 2006)
Pharmacogenetics and genomics |
Pharmacokinetics and drug disposition |
Pharmacodynamics and drug action |
Clinical pharmacology grand rounds |
Letter to the Editor |
Notes of the American Society for Clinical Pharmacology and Therapeutics
Commentary
Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk
Eric P. Brass MD, PhD, Roger J. Lewis MD, PhD, Raymond Lipicky MD, James Murphy PhD and William R. Hiatt MD
Clin Pharmacol Ther 79: 165-172; doi:10.1016/j.clpt.2005.11.012
Pharmacogenetics and genomics
Variations in the 
2A-adrenergic receptor gene and their functional effects
Daniel Kurnik MD, Mordechai Muszkat MD, Chun Li PhD, Gbenga G. Sofowora MD, Joseph Solus PhD, Hong-Guang Xie MD, PhD, Paul A. Harris PhD, Lan Jiang MSc, Chara McMunn BS, Patrick Ihrie MS, Elliott P. Dawson BS, Scott M. Williams PhD, Alastair J.J. Wood MD and C. Michael Stein MD
Clin Pharmacol Ther 79: 173-185; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.10.006
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics
David A. Katz PhD, Robert Carr PhD, David R. Grimm PhD, Hao Xiong PhD, Rhonda Holley-Shanks BS, Toby Mueller MS, Brenda Leake BS, Qiang Wang PhD, Lixin Han PhD, Perry G. Wang PhD, Timi Edeki MD, PhD, Leonardo Sahelijo MD, Thao Doan MD, Andrew Allen MD, Brian B. Spear PhD and Richard B. Kim MD
Clin Pharmacol Ther 79: 186-196; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.003
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population
Soo-Chin Lee MD, Swee-Siang Ng BSc, Johannes Oldenburg MD-PhD, Pei-Yi Chong BSc, Simone Rost PhD, Jia-Yi Guo MSc, Hui-Ling Yap, Sheila Clare Rankin BPharm, Hui-Boon Khor BPharm, Tiong-Cheng Yeo MD, Kheng-Siang Ng MD, Richie Soong PhD and Boon-Cher Goh MD
Clin Pharmacol Ther 79: 197-205; doi:10.1016/j.clpt.2005.11.006
Pharmacokinetics and drug disposition
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans
Stefan Oswald PhD, Sierk Haenisch PhD, Christiane Fricke, Thomas Sudhop MD, Cornelia Remmler PhD, Thomas Giessmann MD, Gabriele Jedlitschky PhD, Ulrike Adam PhD, Eike Dazert PhD, Rolf Warzok MD, Wolfram Wacke MD, Ingolf Cascorbi PhD, MD, Heyo K. Kroemer PhD, Werner Weitschies PhD, Klaus von Bergmann MD and Werner Siegmund MD
Clin Pharmacol Ther 79: 206-217; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.004
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates
Girum L. Lemma MD, Zaiqi Wang MD, PhD, Mitchell A. Hamman BS, Narjis A. Zaheer MS, J. Christopher Gorski PhD and Stephen D. Hall PhD
Clin Pharmacol Ther 79: 218-230; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.001
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide
Lauri I. Kajosaari MB, Mikko Niemi MD, Janne T. Backman MD and Pertti J. Neuvonen MD
Clin Pharmacol Ther 79: 231-242; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.002
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir
Kerry E. Culm-Merdek, Lisa L. von Moltke, Lu Gan, Kelly A. Horan, Robyn Reynolds, Jerold S. Harmatz, Michael H. Court and David J. Greenblatt
Clin Pharmacol Ther 79: 243-254; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.009
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans
Julie Grenier MSc, Caroline Fradette PhD, Gaetano Morelli MD, Gerald J. Merritt PharmD, Manon Vranderick DEC and Murray P. Ducharme PharmD
Clin Pharmacol Ther 79: 255-262; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.010
Pharmacodynamics and drug action
Calcitonin gene–related peptide–induced vasodilation in the human forearm is antagonized by CGRP8-37: Evaluation of a human in vivo pharmacodynamic model
Floris H.M. Vanmolkot MD, Bart J.E.P. Van der Schueren MD and Jan N.J.M. de Hoon MD, PhD
Clin Pharmacol Ther 79: 263-273; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.005
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: Influence of the G-protein 
3 subunit (GNB3) C825T polymorphism
Anna Mitchell MD, Uljana Rushentsova, Winfried Siffert MD, Thomas Philipp MD and Rene R. Wenzel MD
Clin Pharmacol Ther 79: 274-281; advance online publication, February 3, 2006; doi:10.1016/j.clpt.2005.11.008
Clinical pharmacology grand rounds
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene
Jeanna M. Marraffa PharmD, Li Lang PhD, Gilbert Ong MD and David F. Lehmann MD, PharmD
Clin Pharmacol Ther 79: 282-286; advance online publication, February 7, 2006; doi:10.1016/j.clpt.2005.11.014
Letter to the Editor
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3
Mia Sandberg Lundblad PhD, Staffan Ohlsson MD, Peter Johansson RN, Pierre Lafolie MD, PhD and Erik Eliasson MD, PhD
Clin Pharmacol Ther 79: 287; doi:10.1016/j.clpt.2005.11.007
Notes of the American Society for Clinical Pharmacology and Therapeutics
A message from the ASCPT membership committee chairperson
Clin Pharmacol Ther 79: 289; doi:10.1016/j.clpt.2005.12.291
